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Abstract
Most tumor cells reprogram their glucose metabolism as a result of mutations in oncogenes and tumor suppressors, leading
to the constitutive activation of signaling pathways involved in cell growth. This metabolic reprogramming, known as
aerobic glycolysis or the Warburg effect, allows tumor cells to sustain their fast proliferation and evade apoptosis. Interfering
with oncogenic signaling pathways that regulate the Warburg effect in cancer cells has therefore become an attractive
anticancer strategy. However, evidence for the occurrence of the Warburg effect in physiological processes has also been
documented. As such, close consideration of which signaling pathways are beneficial targets and the effect of their inhibition
on physiological processes are essential. The MAPK/ERK and MAPK/JNK pathways, crucial for normal cellular responses
to extracellular stimuli, have recently emerged as key regulators of the Warburg effect during tumorigenesis and normal
cellular functions. In this review, we summarize our current understanding of the roles of the ERK and JNK pathways in
controlling the Warburg effect in cancer and discuss their implication in controlling this metabolic reprogramming in
physiological processes and opportunities for targeting their downstream effectors for therapeutic purposes.
Introduction
Cellular metabolism is the process by which a living cell
converts nutrients into energy or new macromolecules
through a series of biochemical reactions, known as cata-
bolic pathways and anabolic pathways, respectively [1].
Through catabolic pathways, carbon fuels such as glucose,
fatty acids, and glutamine are broken down to generate
energy in the form of adenosine triphosphate (ATP), which
is used to maintain cellular functions and construct new
cellular components [1, 2]. There are two major ATP-
producing pathways in mammalian cells, glycolysis and
oxidative phosphorylation (OXPHOS) [3]. These two
metabolic pathways function in concert to provide energy
for cellular and tissue homeostasis. During glycolysis, a
normal differentiated cell oxidizes glucose into pyruvate,
which enters the mitochondria to be further oxidized to
carbon dioxide in the tricarboxylic acid (TCA) cycle, pro-
ducing the reduced electron carriers nicotinimide adenine
dinucleotide (NADH) and flavin adenine dinucleotide
(FADH2). NADH and FADH2 are then used during
OXPHOS to generate 36 molecules of ATP per molecule of
glucose. OXPHOS is the main ATP-producing pathway in
normal cells and is strictly dependent on the presence of
oxygen [3]. In fact, in the absence of oxygen, the pyruvate
produced by glycolysis is converted to lactate with a net
production of two molecules of NADH and only two
molecules of ATP. Such a low ATP-producing pathway is
referred to as anaerobic glycolysis or glucose fermentation
and takes place in the cytoplasm. Thus, to survive in low
oxygen conditions, a normal differentiated cell re-adjusts its
glucose metabolism by shifting toward anaerobic glyco-
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this inefficient ATP-producing pathway as their chief
manner of energy harvest even in the presence of sufficient
levels of oxygen [4–6]. This is not a new concept as it was
anticipated by Otto Warburg more than 90 years ago when
he observed that tumor slices and ascites cancer cells dis-
play an enhanced rate of glycolysis and produce larger
amount of lactate compared to their normal counterparts
despite the presence of adequate levels of oxygen for
mitochondrial respiration [7]. Subsequent works have
revealed that this metabolic phenomenon is not restricted to
cancer cells, but it is a common metabolic feature among all
mammalian cells during periods of rapid proliferation
[8–10].
Over the past decade, aerobic glycolysis has taken center
stage in cancer research, because it is characteristic of
essentially all types of cancer as well as its implications for
cancer diagnosis and monitoring [4–6, 11–14]. It is now
appreciated that aerobic glycolysis in cancer occurs down-
stream of molecular signaling pathways, often driven by
mutations in oncogenes or tumor suppressors [15–18].
Evidence have pointed out that signaling pathways invol-
ving oncogenes and tumor suppressors play a direct role in
promoting the conversion of energy metabolism to aerobic
glycolysis in addition to their well-known functions in
inducing aberrant cell proliferation or attenuating apoptosis
[19–22]. Among the many signaling pathways that respond
to oncogenic mutational events and regulate proliferation
and apoptosis as well as aerobic glycolysis are members of
the mitogen-activated protein kinases (MAPKs) family.
There are three well-characterized subfamilies of MAPKs in
mammals: the extracellular signal-regulated kinases
(ERKs), the c-Jun N-terminal kinases (JNKs), and the p38
kinases [23]. Activation of each MAPK signaling follows a
three-tier kinase module in which a MAP3K phosphorylates
and activates a MAP2K, which in turn phosphorylates and
activates a MAPK. Once activated, the MAPKs control a
diversity of cellular responses, such as proliferation, dif-
ferentiation, cell death, and survival [23, 24].
Of the three types of MAPKs, ERKs and JNKs have
been recently shown to regulate the redirecting of energy
harvest to glycolysis in both malignant and highly pro-
liferative cells by affecting the activity of key metabolic
regulators. Here we provide a comprehensive overview of
the functional implications and our current knowledge of
the role of ERK and JNK signaling pathways in regulating
glucose metabolism of highly proliferating cells in cancer
and some physiological contexts, such as inflammation and
immunity as well as tissue development.
The glycolytic pathway and its regulation
Most mammalian cells use glucose as the primary carbon
sources for the production of ATP and synthesis of cellular
components, such as proteins, lipids, and nucleic acids [25–
27]. They normally take up glucose from extracellular fluid
into the cell only when stimulated by extracellular growth
factors to growth and divide [28–31]. For example, the
binding of growth factors to receptor tyrosine kinases
(RTKs) activates the phosphatidylinositol 3-kinase (PI3K)/
Akt pathway to stimulate cellular glucose uptake and gly-
colysis along with cell growth and survival [19, 32] by
enhancing both the transcriptional expression and translo-
cation to the cell surface of glucose transporters (GLUTs)
[15, 16, 33]. Once in the cell, glucose is phosphorylated by
the first enzyme of the glycolytic pathway hexokinase (HK)
to form glucose-6-phosphate (G6P), which in turn serves as
an allosteric inhibitor of HK (Fig. 1). HK is stimulated
following activation of Akt, so that PI3K/Akt signaling not
only facilitates the increase in glucose uptake but also
enables glucose progression through the glycolytic pathway
[17, 18, 31, 34]. G6P has then three possible metabolic fates
within the cell. It can be converted into fructose-6-
phosphate (F6P) in the glycolytic pathway or can be oxi-
dized by the pentose phosphate pathway (PPP) or enter the
synthesis pathway of glycogen, a storage form of glucose
(reviewed in ref. [35]) (Fig. 1). If a cell is instructed to
continue glycolysis, F6P is further phosphorylated by the
enzyme phosphofructokinase 1 (PFK1) to form fructose
1,6-biphosphate (F1,6BP), which then is cleaved into two
triose phosphates, glyceraldehyde 3-phosphate (GAP) and
dihydroxyacetone phosphate (DHAP) (Fig. 1) [2, 3]. Unlike
GAP, which is the substrate for the next reaction in gly-
colysis, DHAP does not undergo direct glycolysis. It can
either be used to generate glycerol-3-phosphate (G3P), an
important precursor for the synthesis of structural lipids of
cell membranes, or can proceed further along the glycolytic
pathway via its conversion to GAP by triose phosphate
isomerase. As a result, oxidation of one molecule of glucose
forms two molecules of GAP, both of which are converted
into pyruvate in a sequence of five reactions that generates
ATP and NADH (Fig. 1) [2, 3]. The final reaction in this
sequence is the conversion of phosphoenolpyruvate (PEP)
to pyruvate, which can then enter into TCA cycle by its
conversion to acetyl-coenzyme A (acetyl-CoA) or be con-
verted into lactate depending on cell type and availability of
oxygen [2, 3]. The conversion of PEP to pyruvate is cata-
lyzed by pyruvate kinase (PK), a homotetrameric enzyme
that exists in mammals as four isoforms (PKL, PKR,
PKM1, and PKM2) with different expression patterns and
regulatory mechanisms [36–42]. Unlike PKM1, which is
constitutively active and insensitive to allosteric effectors,
the PKM2, PKL, and PKR isoforms are subject to allosteric
regulation that affects enzyme activity by the direct binding
of effectors. For example, the glycolytic intermediate
F1,6BP stimulates PKM2 by increasing its affinity for PEP
(the catalytic substrate of PK), promoting tetramerization,
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and stabilizing the tetrameric active conformation of PKM2.
Conversely, PKM2 is inhibited by the binding to tyrosine
phosphorylated peptides, which induce the release of
F1,6BP resulting in the stabilization of the inactive dimeric
conformation of PKM2, an event associated with low PK
activity [36]. Besides being allosterically regulated by
diverse metabolites, PKM2 is also negatively regulated by
covalent modifications, including phosphorylation, acet-
ylation, and oxidation. It is now appreciated that low PKM2
activity in cells allows the accumulation of glycolytic
Fig. 1 Schematic diagram of glycolysis. Schematic drawing shows the
steps and specific enzymes of the glycolytic pathway that converts
glucose in pyruvate through a series of enzymatic reactions catalyzed
by hexokinase (HK), phosphoglucose isomerase (PGI), phospho-
fructokinase (PFK), aldolase (ALDOA), glyceraldehyde 3 phosphate
dehydrogenase (GAPDH), phosphoglycerate kinase (PGK), phos-
phoglycerate mutase (PGM), enolase (ENO), and pyruvate kinase
(PK). Lactate dehydrogenase (LDH) converts pyruvate in lactate.
Shown are also the biosynthetic pathways that originate from glyco-
lytic intermediates
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intermediates upstream of the PK reaction that can be used
as precursors for the synthesis of nucleotides, amino acids,
and fatty acids (Fig. 1) (reviewed in ref. [43]). Therefore,
maintaining a low PKM2 activity is particularly important
for highly proliferating cells, such as many cancer cells, that
require a copious supply of nucleotides, amino acids, and
lipids for biomass duplication. Paradoxically, the low level
of PKM2 activity in rapidly proliferating cells is associated
with an increased conversion of pyruvate into lactate with
concomitant generation of NAD+ from NADH in an
enzymatic reaction catalyzed by lactate dehydrogenase A
(LDHA). As NAD+ is consumed by glyceraldehyde-3-
phosphate dehydrogenase activity in a reaction that gen-
erates 1,3-biphosphoglycerate from GAP in glycolysis (Fig.
1), an efficient regeneration of NAD+ is required to main-
tain the continuity of the glycolytic flux [44]. Therefore, it
appears that pyruvate is converted into lactate to sustain
high glycolytic flux, regenerating NAD+. Interestingly,
NAD+ is not only required to enable glycolysis but is also
needed for nucleotide and amino acid biosynthesis path-
ways that branch from glycolysis [26, 44–47]. Therefore,
during rapid cell proliferation, an efficient enzymatic
activity of LDHA provides an advantage to cells by
regenerating NAD+.
The Warburg effect: a novel perspective
It has long been known that normal highly proliferating and
tumor cells display the Warburg-like metabolic phenotype,
which is characterized by high rate of glucose uptake and
conversion to lactate under aerobic conditions [20, 44, 48].
One of the most important debates about this metabolic
phenotype is that aerobic glycolysis is an inefficient meta-
bolic pathway generating less ATP per single molecule of
glucose than that generated through OXPHOS and, plainly,
aerobic glycolysis cannot cope with the high cellular
demand of energy required during fast cell proliferation. A
number of possible explanations have been proposed to
account for the Warburg metabolism of proliferating cells.
One possible explanation is that aerobic glycolysis essen-
tially generates more ATP by producing it at a faster rate
than OXPHOS [25, 44]. Thus it appears that the theoretical
inefficiency of energy generation of glycolysis is counter-
weighed by the rapid production of ATP. Additionally, an
increase in glycolytic flux is believed to be advantageous
for proliferating cells with high demand for reducing
equivalents (such as NADPH) and cellular macromolecules
(such as DNA, proteins, and lipids) [49]. This is because an
accelerated glycolytic flux can lead to an accumulation of
glycolytic intermediates, which can be channeled into bio-
synthetic pathways. For example, G6P, the first glycolytic
intermediate, can be oxidized through the PPP to generate
the nucleotide precursor ribose-5-phosphate and NADPH,
which is used for lipid biosynthesis and scavenging of
reactive oxygen species (ROS) produced during fast cell
proliferation (Fig. 1) [26, 32, 50]. Similarly, DHAP and
3PG, other two glycolytic intermediates, can leave the
glycolytic flux and participate in the phospholipids and
serine biosynthesis pathway, respectively (Fig. 1). It is
important to note, however, that these glycolytic inter-
mediates will not accumulate and branch off into their
respective biosynthetic pathways unless the final enzymatic
reaction in glycolysis (the conversion of PEP into pyruvate)
is slowed down. To achieve this, proliferating cells and
many cancer cell types predominantly express and use
PKM2, which, as discussed above, has a low PK activity
and therefore is less efficient in converting PEP to pyruvate
than PKM1, thereby allowing for upstream glycolytic
intermediates to accumulate and branch off into biosyn-
thetic pathways. As such, PKM2 expression and its low
activity is known to promote cancer cell proliferation [36–
42], although recent studies in mouse cancer models have
led to opposing conclusions [51]. For example, absence of
PKM2 accelerates tumor formation in a Brca1-loss-driven
model of breast cancer [40], in a mouse model of medul-
loblastoma [52], and results in spontaneous hepatocellular
carcinoma (HCC) development in aged mice [53], indicat-
ing that PKM2 negatively regulates tumorigenesis. How-
ever, other in vivo studies support the notion that PKM2 has
as an oncogenic function in leukemia [54] and soft tissue
sarcoma formation [55]. It therefore seems likely that the
function of PKM2 in cancer development depends on the
cancer type. Taken together, the findings described above
support the hypothesis that increased aerobic glycolysis is a
metabolic strategy to improve the availability of NADPH
and metabolic substrates needed for rapid biomass synthesis
during fast cell proliferation. Increases in the rates of gly-
colysis have also beneficial antioxidant role for cells, gen-
erating NADPH essential for protecting cells from oxidative
damage driven by increased cell proliferation (Fig. 1) [44,
56].
Although the Warburg effect has now been widely
accepted as an emerging hallmark of cancer, it is a dis-
tinctive feature of many highly proliferating normal cells
and fulfills a number of homeostatic functions, which
include brain functionality, immune responses, and tissue
remodeling in embryogenesis (Fig. 2) [56–62]. Thus the
Warburg-like glucose metabolism has probably evolved not
only to satisfy the specific biosynthetic needs of any dif-
ferentiated cell type during rapid proliferation but also to
regulate cell fate and functions (Fig. 2). Because of their
increased biosynthetic needs, many types of cancer cells,
unlike their normal counterparts, adopt this tightly con-
trolled metabolic strategy to support their own deregulated
proliferation. Therefore, targeting enhanced glycolysis in
cancer represents a worthwhile therapeutic strategy. In this
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respect, it worth to note that direct inhibition of metabolic
enzymes could cause adverse cellular effects and unwanted
toxicity because of their relevance to normal physiological
functions, such as immunity and brain development [56–
62]. Therefore, effective treatment of highly glycolytic
tumors will require maintaining a delicate balance between
suppressing deleterious functions of glycolytic enzymes and
interfering with cellular physiology (Fig. 2). Treatments
aimed at inhibiting specific isoforms of certain glycolytic
enzymes, the expression of which is associated with cancer,
or targeting metabolic enzymes in a deregulated metabolic
pathway specific to cancer cells may have better therapeutic
efficacy and reduce undesired side effects. We refer the
interested readers to dedicated reviews for a detailed dis-
cussion of few examples of such metabolic inhibitors that
have shown promising outcomes in animal models [35, 63–
65]. Therefore, a better understanding of how the Warburg-
like metabolism is regulated in normal physiological con-
texts could lead to more effective ways of targeting meta-
bolic pathways without toxicity (Fig. 2).
The Warburg effect in normal cellular functions
The role of the Warburg effect in stem cells
Research on stem cell biology recently provided compelling
evidence in support of a role for aerobic glycolysis in the
regulation of cell differentiation in various cellular contexts
(Fig. 2) [66–72]. During the cellular differentiation pro-
gram, pluripotent embryonic stem cells (ESCs) proceed
Fig. 2 Cellular functions associated with aerobic glycolysis: to pro-
liferation and beyond. Aerobic glycolysis has been widely linked to
cell proliferation, especially in cancer cells where it serves to generate
sufficient energy (by means of ATP) and synthesis of building blocks
needed for cell growth and division. Aerobic glycolysis provides also
antioxidant capacity to many different cells (i.e., cancer cells, immune
cells, neurons, and stem cells) to protect against oxidative stress-
induced apoptosis and provide survival advantages. Other than serving
as an antiapoptotic pathway, aerobic glycolysis is crucially required for
specific cellular functions: (i) biosynthesis of neurotransmitters, (ii)
activation and differentiation of specialized cells, (iii) antimicrobial
activity, and (iv) naive to primed pluripotency
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through several stages, becoming more specialized (differ-
entiated) at each step. Recent investigations indicate that
ESCs display elevated rates of glycolysis with lactate pro-
duction before differentiation and gradually shift toward
OXPHOS as they mature and become terminally differ-
entiated [66–69]. For example, Harris and colleagues [69],
using embryonic Xenopus retinal tissue, demonstrated that
dividing retinal progenitors are more reliant on aerobic
glycolysis when compared with more differentiated cells. A
similar switch from glycolytic to oxidative metabolism
accompanied by increases in the expression of mitochon-
drial genes has been reported to be essential for the differ-
entiation of murine ESCs to cardiomyocytes [70, 71], as
well as human neuronal progenitor cells to differentiated
neurons [66]. Although the exact mechanisms underlying
such metabolic shift during cell differentiation is not fully
clear, recent works have proposed several potential
mechanisms. In the embryonic heart, immature cardio-
myocytes display an open mitochondrial permeability
transition pore (mPTP) and a glycolytic phenotype [72].
Pharmacologic and genetic closing of the mPTP cause
structure and function maturation of mitochondria and result
in accelerated cardiomyocyte differentiation, suggesting
that mPTP dynamics regulate cardiomyocyte differentia-
tion. Moreover, gene-targeting studies in mice revealed a
key role for the nuclear receptor peroxisome proliferator-
activated receptor-α (PPAR-α) and its cardiac-enriched
coactivator protein, proliferator-activated receptor γ-coacti-
vator (PGC)-1β, inducing the expression of mitochondrial
genes and suppressing the expression of GLUT and gly-
colytic enzymes during cardiomyocyte maturation from
fetal to adult [73].
In contrast, a metabolic switch from oxidative to glyco-
lytic metabolism with high levels of lactate production has
been found to take place during reprogramming of somatic
cells to induced pluripotent stem cells (iPSCs), in vitro [74,
75]. Differentiated somatic cells are highly dependent on
mitochondrial OXPHOS for energy production and need a
switch to glycolysis when they enter a pluripotent state
through reprogramming. Recent studies demonstrated that
such switch, which is accompanied by an upregulation of
glycolytic genes, precedes the expression of pluripotent
genes during the reprogramming [74, 75]. This suggests that
a Warburg-like metabolic phenotype is important for the
acquisition of pluripotency, the ability of a stem cell to
differentiate into any cell type of the adult body. In line with
this, inhibition of glycolysis via various pharmacologic
means attenuates the somatic cell reprogramming to iPSC,
whereas the induction of aerobic glycolysis enhances the
efficiency of iPSC generation [74–77]. Thus it appears that
an increase in glycolysis accompanied by a low mitochon-
drial activity drives the somatic cell reprogramming pro-
cess. Mechanistically, two transcription factors, hypoxia-
inducible factors (HIFs) and c-Myc, the main positive reg-
ulators of aerobic glycolysis in cancer [13, 21, 30], have
emerged as factors essential for the maintenance
and acquisition of a pluripotent state [76, 77]. Taken toge-
ther, the findings described above indicate that shifts
between glycolysis and mitochondrial OXPHOS are inter-
twined with cell differentiation and reprogramming to
pluripotency.
The role of the Warburg effect in the immune response
Similar to cancer cells, inflammatory immune cells such as
M1 type macrophages, neutrophils, and dendritic cells
exhibit a metabolic shift to glycolysis when activated
through Toll-like receptors (TLRs) upon pathogen recog-
nition [56–61, 78]. This leads to the production of various
pro-inflammatory cytokines including interleukin-1β (IL-
1β) and tumor necrosis factor-α (TNF-α). This metabolic
shift involves an increase in the expression of GLUT1
(SLC2A1) gene and specific glycolytic genes as well as
elevated lactate production accompanied by a decline in
mitochondrial activity. Additionally, flux into the PPP,
which allows the synthesis of nucleotides and NADPH
generation, also enhances [57, 58, 79, 80]. It is now
appreciated that the glycolytic metabolism allows mature
activated immune cells to sustain rapid ATP production and
satisfy the high demand of biosynthetic precursors asso-
ciated with an acute inflammation or antibacterial response.
Indeed, unlike cancer cells, activated immune cells are not
highly proliferative, implying that a high proliferation rate is
not the only explanation for why aerobic glycolysis is
selected for in immune cells upon TLR activation [78]. In
TLR-activated macrophages, for example, this metabolic
choice may reflect the important role of mitochondrial ROS
(mROS) in their bactericidal activity [58, 81, 82]. mROS
are generated when electrons prematurely exit the electron
transport chain and incompletely reduces oxygen to form
superoxide (O2
–), thus compromising the mitochondrial
synthesis of ATP. It seems, therefore, that one potential
benefit of favoring glycolysis over mitochondrial OXPHOS
for ATP production would be to compensate for reduced
mitochondria ATP production as mitochondria is used to
produce ROS for the clearance of intracellular bacteria [58,
81, 82]. More recently, the metabolic shift toward the gly-
colytic pathway has been shown to be essential for the
migration of activated macrophages to the sites of inflam-
mation. Pharmacological inhibition of the glycolytic path-
way or uptake of glucose suppresses the migration of
murine macrophages to inflamed tissue. Moreover, PKM2
was found to localize in filopodia and lamellipodia, two
cytoskeleton structures essential for cell migration [83].
This indicates that glycolysis is positively associated with
the migratory properties of macrophages.
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The important role for the glycolytic pathway in immune
responses was also revealed by studies on T cells that carry
the CD4 antigen. In the presence of specific cytokine
microenvironment, this specialized population of T cells
(CD4+ T cells) become activated and can differentiate into
either effector T cells (Teffs) or regulatory T cells (Tregs)
following the engagement of the T-cell antigen receptor
(TCR) and co-stimulatory receptors [59, 60]. Whereas
Teffs, which include T helper type 1 (Th1), Th2, and Th17
cell subset, are involved in the inflammatory responses,
induced Tregs (iTregs) limit inflammation and possess
immunoregulatory functions [59, 60]. It is now clear that
Teffs and iTregs adopt distinct metabolic programs to attain
their opposing functions, with Teffs expressing high surface
levels of the GLUT1 and being highly glycolytic, whereas
Tregs express low levels of GLUT1 and exhibit oxidative
metabolism [84]. Importantly, inhibition of glycolysis has
been shown to block the development of Th17 cell subset
and at the same time to promote Tregs generation, indi-
cating that glycolysis is crucial for controlling T cell lineage
choices [58, 85, 86]. Moreover, glycolysis is not required to
promote proliferation and survival of T cells but is needed
instead for T cell migration and effector functions as well as
antitumor immunity [58, 60, 87].
The close relationship between glycolysis and antitumor
immunity has received considerable attention in the past
few years since the reported success of adoptive T cell
immunotherapy [88]. Insufficiency of glucose in the tumor
microenvironment caused by high rates of glucose uptake in
tumor cells has been shown to suppress the antitumor
response of tumor-infiltrating T cells, indicating a
mechanism by which glycolytic metabolism of tumor cells
directly suppresses the antitumor T cell function. More
importantly, enforcing the production of the glycolytic
metabolite PEP in such suppressed infiltrating T cells
restored the effectiveness of their antitumor responses,
which resulted in suppression of tumor growth upon
adoptive transfer [89]. Thus glycolysis seems to have an
important contribute in the choice between pro-
inflammatory and anti-inflammatory CD4+ T cell subsets
and their antitumoral functions. As such, manipulating the
glycolytic pathway in tumor and/or T cells may be bene-
ficial in enhancing the efficacy of adoptive cancer immu-
notherapy. Along these lines, the swift to glycolysis has also
been shown to be a critical event in M1 and M2 macro-
phage polarization, a tightly controlled process by which
macrophages acquire distinct phenotypes and functional
capabilities in response to diverse tissue-derived micro-
environmental signals [90]. While M1 macrophages have an
inflammatory phenotype with a strong antimicrobial and
antitumor activity, M2 macrophages prevent excess
inflammation and promote tissue repair and remodeling as
well as antiparasitic immunity and tumor progression [91].
It is worth noting that a shift in the balance between these
polarization states of macrophages is central to a spectrum
of human diseases, including obesity and cancer. For
example, diet-induced obesity has been shown to be a
consequence of an inappropriate accumulation of proin-
flammatory M1 state in the adipose tissue that leads to
insulin resistance [92], whereas chronic weight loss was
found to result from an excess presence of M2 macrophages
in the adipose tissue [93]. Moreover, a high density of
tumor-associated macrophages, which closely resemble the
M2 state, has been shown to associate with tumor pro-
gression and poor prognosis in various tumour types [94].
Interestingly, inflammatory M1 macrophages favor glyco-
lysis over mitochondrial OXPHOS for rapid pathogen
killing, whereas anti-inflammatory M2 macrophages use
OXPHOS as the main ATP-producing pathways [58, 60].
As such, blocking mitochondrial ATP production with oli-
gomycin resulted in phenotypic repolarization of M2 to
M1 cells [95]. Therefore, broader understanding of the
metabolic features of M1 and M2 macrophages could
indicate new targets for manipulating macrophage polar-
ization in a therapeutic context. Taken together, the findings
described above illustrate the importance of the Warburg
effect in promoting the effector functions of immune cells
(Fig. 2). Importantly, the signaling mechanisms that reg-
ulate aerobic glycolysis are the subject of intense ongoing
research. Several studies showed that activation of certain
signaling pathways, such as ERK and JNK pathways, can
directly or indirectly affect the transcriptional or post-
transcriptional regulation of enzymes involved in glycolysis
and OXPHOS as well as their anabolic pathway branches.
A stepwise description of the roles of these two MAPK
pathways in promoting the Warburg effect is outlined in the
following sections.
The ERK signaling and the Warburg effect
In addition to their recognized role in controlling cell pro-
liferation and survival, many of the signaling pathways
downstream of both oncogenes and tumor-suppressor genes
can regulate the glucose metabolism [6, 32]. For example,
the ERK-MAPK signaling pathway, which is activated by
the RAS oncoproteins (HRAS, KRAS, and NRAS) and
positively associated with cell proliferation and survival
[23, 24], has been shown to promote the Warburg effect
[96]. Like other MAPK signaling pathways, the ERK
pathway is activated by a series of phosphorylation events
(i.e., the MAPK model) that occur downstream of a variety
of activated receptor types including RTKs in response to
extracellular stimuli such as growth factors (Fig. 3). The
initiating kinases (i.e., the MAP3K) are members of the
RAF family, which include ARAF, BRAF, and CRAF, and
often activated as a result of their interaction with active
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GTP-bound RAS proteins. This interaction, which occurs at
the inner leaflet of the plasma membrane, leads to the for-
mation of active homodimers or heterodimers of the RAF
protein kinases (Fig. 3). Once activated, RAF kinases
phosphorylate and activate components of the MAP2K
module, such as MEK1 and MEK2, which in turn, activate
the two MAPK protein kinases, ERK1 and ERK2, through
phosphorylation of both tyrosine and threonine residues
present in a conserved tripeptide motif (Thr-Glu-Tyr) within
their activation loop. Upon activation, ERK1 and ERK2
phosphorylate and activate a large number of nuclear and
non-nuclear proteins, including transcription factors of the
ETS family, the ternary complex factor transcription factors,
c-Myc, signal transducer and activator of transcription
factor 3, nuclear factor (NF) of activated T cells, as well as
cell survival regulators of the BCL-2 protein family in the
Fig. 3 The control of aerobic glycolysis by ERK and JNK signaling
pathways in proliferating cells. Glycolysis (red-dotted shape) starts
when glucose enters the cells through GLUTs and is converted into
glucose-6-phosphate by the first glycolytic enzyme hexokinase (HK).
The final product of glycolysis is pyruvate. Its production is tightly
regulated by the glycolytic enzyme PKM2, whose activation, con-
formational state, and cellular localization is tightly regulated by
posttranslational modifications, which includes phosphorylation,
cysteine oxidation, and acetylation. Pyruvate could be further oxidized
in the mitochondrion through its conversion to acetyl-CoA for sub-
sequent oxidation in the tricarboxylic acid (TCA) cycle. The shunting
of pyruvate into the mitochondrion is regulated by the activity of
pyruvate dehydrogenase (PDH), which in turn is negatively regulated
by pyruvate dehydrogenase kinases (PDKs) under hypoxia. In pro-
liferating cells, a largest amount of pyruvate is converted to lactate
contributing to the Warburg effect. The formation of lactate, catalyzed
by lactate dehydrogenase (LDH), is necessary for the rapid regenera-
tion of NAD+ from NADH, which is then reused to maintain active the
glycolytic flux. Aerobic glycolysis of cells in multicellular organisms
is regulated by both extracellular and intracellular signaling pathways.
Engagement of growth factors to their receptors signals activation of
PI3K/AKT pathway and the phosphorylation cascade of RAS/BRAF/
MEK/ERK (green-dotted shape). The BRAF/MEK/ERK signaling
cascade can be also activated by oncogenic mutations and culminates
with activation and translocation of ERK to the nucleus, which reg-
ulates the expression and activity of transcription factors that directly
control the expression of glycolytic enzymes in cancer cells. This
network of transcription factors, including hypoxia-inducible factor-1α
(HIF-1α) and c-Myc, drives the Warburg effect downstream of
oncogenic BRAF(V600E) mutation in melanomas. Binding and acti-
vation of MEK by BRAF is further enhanced after accumulation in the
cytoplasm of acetoacetate, a byproduct of ketogenesis—a biochemical
process by which cells produce ketone bodies by the breakdown of
fatty acids and ketogenic amino acids such as glutamine (gray-dotted
shape). RAS-mediated oncogenesis and cellular stress also contribute
to the activation of JNK cascade (blue-dotted shape). Once activated,
upstream MAP3K kinases (e.g., TAK1 and MLK3) phosphorylate and
activate MKK4 and MKK7, which in turn phosphorylate and stimulate
the activity of distinct JNK isoforms. Upon activation, each JNK
protein delivers different cellular activities. While JNK1 negatively
regulates aerobic glycolysis via direct phosphorylation of PKM2 and
PDH, JNK2 positively controls aerobic glycolysis via upregulation of
PARP14, a direct inhibitor of JNK1-mediated phosphorylation of
PKM2 in cancer cells. Notably, JNK1 activation depends also on the
formation and accumulation of mitochondrial and cellular ROS
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mitochondria [23, 24]. These proteins regulate a diversity of
cellular processes, such as cell proliferation, growth, sur-
vival, differentiation, and motility, whose deregulation has
been associated with cancer [23, 24, 97].
Indeed, constitutive activation of ERK1 and
ERK2 signaling is frequently observed in human cancers
due to mutations in genes that encode RTKs, RAS, BRAF,
CRAF, MEK1, and MEK2 [24, 98]. In melanoma, for
example, up to 70% of these tumors have point mutations in
the BRAF gene, the majority of which lead to a single
amino acid substitution of valine for glutamic acid at
position 600 (the BRAFV600E mutation). These mutations
favor the active structural conformation of BRAF kinase,
causing the constitutive activation of ERK1/2 pathway,
which then activates proliferative programs and promotes
the aerobic glycolytic phenotype via induction of tran-
scriptional regulators of glycolysis, the TCA cycle, and
macromolecular biosynthesis (Fig. 3) [98]. Among these
transcription factors are c-Myc, which increases the
expression of GLUT1, LDHA, and a number of enzymes in
the glycolytic pathway, as well as HIF-1α, which also
upregulates LDHA and cooperates with c-Myc in the
induction of HK2 [99–101]. c-Myc is also known to induce
expression of enzymes involved in nucleotide and fatty acid
synthesis as well as glutaminolysis, which sustains the pool
of metabolic intermediates in the TCA cycle that in turn can
be used as biosynthetic precursors to generate amino acids
and fatty acids for anabolic growth [102–104]. Moreover, c-
Myc facilitates the glycolytic intermediates flux to the PPP,
serine, and glycine biosynthesis pathways by
promoting PKM2 expression [105]. In line with this,
enforced expression of BRAF(V600E) in melanoma cells
has been shown to upregulate the expression of glycolytic
and PPP enzymes to sustain melanoma cell growth and
proliferation [106]. Interestingly, Haq and collaborators
[107] observed that BRAF(V600E) expression in melano-
mas correlates with decreased expression of oxidative
enzymes, diminished mitochondrial number and function,
and increased production of lactate. The authors also
showed that activated BRAF/ERK pathway promotes gly-
colytic phenotype in melanoma cells by downregulating the
expression of the mitochondrial biogenesis and function
factor, PGC-1α, thereby inhibiting the mitochondrial oxi-
dation [107].
In addition, high levels of serum lactate were observed in
patients with BRAF mutant melanomas [108], providing
evidence of linking oncogenic BRAF/ERK signaling to
aerobic glycolysis in a clinical setting. Activating mutations
in the BRAF gene have also been identified in non-
melanoma tumors, including thyroid, colorectal carcinomas,
lung cancer, and hairy cell leukemia [109], and were linked
to the glycolytic phenotype in both in vitro and in vivo
cancer models [110, 111].
The link between the Warburg effect and the RAF/MEK/
ERK pathway was further confirmed by cellular and
xenograft studies using BRAF inhibitors or MEK inhibitors.
A decrease in the expression levels of various glycolytic
genes, including GLUT1, GLUT3, and HK2, lactate and
ATP production was observed in a panel of BRAF(V600E)
melanoma cell lines treated with the BRAF inhibitor
vemurafenib as well as in samples from patients undergoing
BRAF inhibitor therapy. Such effect was associated with a
decrease in the transcription of ERK1/2 target genes [97].
Importantly, treatment of vemurafenib-resistant
BRAFV600E melanoma cells with vemurafenib in combi-
nation with the pyruvate mimetic dichloroacetate, which
inhibits glycolysis as a consequence of an increase in
glycolysis-derived pyruvate flux into the TCA cycle [112],
was shown to restore the expression of glycolytic enzymes
and re-sensitize these resistant cells to vemurafenib [98],
indicating that glycolysis contributes to resistance to BRAF/
MEK/ERK pathway inhibition in melanoma. A decrease in
glucose uptake, lactate levels, and HK2 expression was also
observed in human cancer cells harboring mutant BRAF
and BRAF-driven melanoma xenografts following MEK1/2
inhibition [113], confirming a positive correlation between
the glycolytic phenotype of cancer cells and BRAF/MEK/
ERK pathway activation.
An important role of ERK1/2 signaling in promoting the
Warburg-like metabolism can also be inferred from studies
in other oncogenic contexts. DePinho and colleagues [114],
using an inducible mouse model of pancreatic cancer driven
by the Kras oncogene, demonstrated that oncogenic acti-
vation of the RAF/MEK/ERK pathway sustains tumor
growth by inducing transcriptional upregulation of key
genes that promote both the uptake and consumption of
glucose to produce lactate, resulting in an increase in gly-
colytic intermediates flux into anabolic pathways, such as
the hexosamine and non-oxidative PPP pathways, which
provide precursors for protein glycosylation and nucleotide
biosynthesis. The ERK-directed transcriptional program
was found to be dependent on c-Myc transcriptional activ-
ity, providing further evidence linking the ERK1/2 signal-
ing to the Warburg-like metabolism in cancer cells [114].
Another intriguing link between the ERK1/2 signaling and
cancer-associated Warburg effect is provided by the gly-
colytic enzyme phosphoglycerate kinase 1 (PGK1) [115].
Activation of ERK1/2 by hypoxia, epidermal growth factor
(EGF) stimulation, mutant BRAF, or KRAS was shown to
induce mitochondrial translocation of PGK1, through
phosphorylation of S203. This phosphorylation event in
turn results in phosphorylation and activation of pyruvate
dehydrogenase kinase (PDK), of which there are four iso-
forms (PDK1–4) [115]. Upon activation, PDK1 inhibits the
enzyme complex pyruvate dehydrogenase (PDH), which
converts pyruvate into acetyl-CoA (the main substrate for
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the TCA cycle), resulting in the suppression of pyruvate
consumption and ROS production in mitochondria and
increased lactate production. Thus, by promoting PGK1
mitochondrial translocation, ERK1/2 enhances aerobic
glycolysis and compromises the TCA cycle, resulting in
brain tumorigenesis (Fig. 3) [115]. In another study, how-
ever, oncogenic activation of ERK1/2 was shown to posi-
tively regulate TCA cycle flux (via PDH) by suppressing
the PDK4 expression. The positive regulation of PDH flux
by ERK1/2 signaling was associated with an increase in cell
proliferation rates [116]. Given that the TCA cycle supplies
substrates for energy production by OXPHOS and inter-
mediates for lipid and amino acid synthesis [32, 103], these
contrasting findings probably reflect the fact that pro-
liferating cells modulate PDH flux through ERK1/2 signal-
ing to suit distinct metabolic needs of each specific cell
type.
Besides affecting metabolic enzymes, ERK1/2 pathway
can also influence cellular metabolism indirectly by con-
trolling the AMP-activated protein kinase (AMPK), a key
regulator of energy homeostasis that is activated under low-
energy conditions by the tumor-suppressor liver kinase B1
(LKB-1) in most cellular contexts [117]. Upon activation,
AMPK inhibits almost all biosynthetic pathways needed for
cell proliferation to decrease ATP consumption and acti-
vates ATP-producing catabolic pathways, thus allowing
cells to restore energy homeostasis [117]. Although acti-
vated AMPK has been shown to enhance glucose uptake
and glycolysis in certain contexts [118], mouse embryo
fibroblasts or cancer cells lacking AMPK activity exhibit an
elevated glucose consumption and lactate production asso-
ciated with increased lipid biosynthesis and ability to form
tumors in vivo [119, 120]. Mechanistically, the transcription
factor HIF-1α has been shown to be required for increased
glycolysis and biosynthesis observed in AMPK-deficient
cells. In line with recent studies in human gastric cancer cell
[121], these observations suggest that AMPK can suppress
the Warburg-like metabolism that underpins tumorigenesis.
In support of this view, downregulation of LKB1-AMPK
signaling by oncogenic signaling pathways that promote the
Warburg-like phenotype has been reported in many cancers
[119]. In BRAF(V600E) melanoma cells, for example,
activated ERK has been shown to phosphorylate LKB1,
rendering this enzyme unable to bind to and activate AMPK
[122, 123] (Fig. 3). The inactivation of LKB1 by ERK has
been shown to be instrumental in BRAF(V600E)-driven
tumorigenesis. The inhibition of the LKB1-AMPK axis by
ERK was also shown to promote cell growth and pro-
liferation in other highly glycolytic cancers [123], providing
further evidence linking ERK1/2 signaling to the metabolic
features of cancer cells.
Constitutive activation of ERK1 and ERK2 by muta-
tional activated RTKs, such as the EGF receptor mutant III
(EGFRvIII), also leads to the Warburg effect phenotype. Lu
and colleagues [96] demonstrated that EGFR-activated
ERK1/2 binds to and phosphorylates PKM2 at Ser37
favoring its nuclear translocation (Fig. 4). Importantly,
ERK1/2 phosphorylates PKM2, but not PKM1, leading to
Pin1-dependent cis-trans isomerization and conversion of
PKM2 from a tetramer to a monomer. In the nucleus, PKM2
couples with transcriptional factors and functions as a
protein kinase that phosphorylates histone H3 for gene
transcription of cyclin D1 and c-Myc, which promotes the
expression of glycolytic enzyme genes (Fig. 4) [96].
However, it is worth noting that c-Myc not only pro-
motes glycolysis but also favors mitochondrial respiration
by enhancing the expression of genes involved in mito-
chondrial structure and biogenesis [104, 124–126]. Indeed,
knockdown of c-Myc in breast cancer cells with stem-like
features was found to be associated with decreases in
mitochondrial mass and oxygen consumption as well as in
the number of mitochondria. The impaired mitochondrial
function was associated with reduced mammosphere for-
mation, which is an assay method to test “stemness” of
cancer cells in vitro and tumor initiation in vivo [127, 128].
Thus both glycolysis and OXPHOS appear to be positively
regulated by c-Myc and essential for tumorigenesis. As a
whole, these examples illustrate that oncogenic alterations
in ERK1/2 signaling pathway, which has a crucial role in
sustaining proliferative programs, determine a metabolic
switch from mitochondrial metabolism to glycolysis in
cancer cells, fulfilling the energetic and biosynthetic
requirements for tumor growth. As such, several therapeutic
approaches targeting this pathway at multiple levels are
currently being tested in clinical trials or used in the clinic
for cancer treatment [129], and their efficacy have been
correlated with the inhibition of glycolysis and/or anabolic
metabolism [130–132].
There is also striking evidence that ERK1/2 activation is
critical for the switch from OXPHOS to glycolysis observed
in activated T cells that, as discussed above, is essential for
T cell effector differentiation and function. Indeed, phar-
macologic inhibition of ERK1/2 activity blocked the
increase in glucose uptake and glycolysis as well as mRNA
expression and activity of the glycolytic enzyme HK
induced by the ligation of the TCR and the co-stimulatory
receptor CD28 [133]. Furthermore, inhibition of ERK1/2
has been shown to impair glucose consumption and lactate
production in macrophages activated by LPS. Mechan-
istically, the decrease in glycolysis appears to be related to
the reduction in the levels of the glycolytic
intermediate fructose-2,6-bisphosphate (F2,6BP) [134], an
allosteric activator of the glycolytic enzyme PFK1 [6].
Thus, by enhancing glycolysis, ERK1/2 signaling
positively controls T cell and pro-inflammatory macrophage
function.
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Fig. 4 ERK- and JNK-mediated phosphorylation of PKM2 is at the
crossroad between proliferation and apoptosis. PKM2 acts as master
regulator of the Warburg effect. Of the many posttranslational mod-
ifications, phosphorylation of PKM2 by either ERK or JNK1 dictates
distinct outcomes. In quiescent cells, PKM2 is present as a tetrameric
protein associated with elevated enzymatic activity. When cells receive
a growth stimulus, activation of ERK drives phosphorylation of tet-
rameric PKM2. Phosphorylated PKM2 is then cis-trans isomerized by
PIN1 allowing dissociation of tetrameric PKM2 to monomers.
Monomeric PKM2 enters the nucleus where it acts as histone-binding
protein allowing gene expression regulation of both glycolytic
enzymes and cell cycle regulators (i.e., c-Myc, cyclin D1). Besides,
accumulation of reactive oxygen species (ROS) in the cytoplasm
promotes activation of JNK1, which can phosphorylate and enhance
PKM2 activation, allowing cells to reduce their antioxidant capacity
and induce apoptosis. Notably, enhanced expression of PARP14 in
cancer cells suppresses JNK1-mediated phosphorylation and activation
of PKM2, providing therefore survival advantages to cancer cells.
PARP14 by suppressing JNK1 activity contributes to maintain low
PKM2 activity and, combined with a robust glycolysis, leads to an
accumulation of glycolytic intermediates, including precursors of
nucleic acids, lipids, and amino acids. This accumulation provides a
metabolic bottleneck allowing glycolytic intermediates to be redirected
toward biosynthesis, fueling through the pentose phosphate pathway
for DNA synthesis and thereby contributing to the rapid cell pro-
liferation seen in tumors
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The JNK signaling and the Warburg effect
Another MAPK subfamily mechanistically linked to the
Warburg effect is the JNK kinase family [102], which
includes three proteins (JNK1, JNK2, and JNK3) that are
encoded by three separate genes, namely, jnk1 (mapk8),
jnk2 (mapk9), and jnk3 (mapk10) [24]. Whereas JNK1 and
JNK2 are ubiquitously expressed in mammalian cells, the
expression of JNK3 is restricted to certain tissues [24]. The
JNK proteins—also known as stressed-activated protein
kinases—are activated by a variety of extracellular stimuli,
including stress, proinflammatory cytokines, growth factors,
pathogens, toxins, and drugs. Similarly to ERK1/ERK2,
activated JNKs can directly phosphorylate a variety of
cytoplasmic and nuclear substrates, which participate in a
diversity of cellular processes, including proliferation, dif-
ferentiation, apoptosis, and survival [135].
It is now appreciated that the functions of each JNK
proteins can either differ or overlap depending on the cell
type [135]. With respect to cancer, for example, JNK2
appears to be a crucial tumor promoter of carcinogen-
induced skin cancer in contrast to JNK1 [136]. Moreover,
JNK2, but not JNK1, is required for the survival of mye-
loma cells [137] and promotes the tumorigenicity of glio-
blastoma cells [138]. Conversely, JNK1 is required for
proliferation of hepatocytes and liver cancer cells in vivo,
while JNK2 appears to be dispensable [139]. Thus JNK
proteins play different and even opposing roles in cancer
development, although functional redundancy between
JNK1 and JNK2 has also been reported [135]. Support
evidence for the latter stems from studies showing that loss
of either JNK1 or JNK2 has no effect on development of B
lymphomas induced by transgenic expression of the c-Myc
oncogene and overall survival rate of c-Myc-transgenic
mice, thus indicating that loss of one JNK protein is com-
pensated for by the other remaining [140]. Redundant or
partially redundant roles for JNK1 and JNK2 proteins have
also been identified in studies of Burkitt’s lymphoma [137,
141] and breast cancer cell lines, as well as mouse model of
breast cancer caused by loss of a single allele of the p53
tumor-suppressor gene [142, 143]. While the findings out-
lined above indicate that JNK proteins can play roles in
tumor development, they also emphasize that JNK1 and
JNK2 have either distinct or redundant functions. Whether
JNK1 and JNK2 differentially affect cancer-associated
metabolic changes is a matter of active investigation.
Despite a connection between JNKs and metabolic dis-
orders (i.e., obesity-induced immune cell recruitment,
inflammation in adipose tissue, insulin resistance, impaired
glucose homeostasis) in mammalians have been widely
described (reviewed in ref. [144]), very little is known about
possible links between the JNK pathway and the metabolic
reprogramming of tumor cells. Recent work from our group
as well as several other laboratories revealed a role for the
JNK pathway in restraining aerobic glycolysis to promote
apoptosis in cancer cells [145]. In HCC cells, for example,
JNK1 activity is suppressed by the antiapoptotic protein
poly(ADP-ribose) polymerase 14 (PARP14), and this sup-
pression appears to be the key determinant for the Warburg-
like phenotype needed for enhanced HCC cell survival
[146]. The inhibition of JNK1 by PARP14 was also shown
to support antioxidant capacity of HCC cells by increasing
NADPH and glutathione levels. At a mechanistic level,
JNK1 stimulates PKM2 activity by enhancing the affinity of
PKM2 for its substrates, PEP and ADP, through phos-
phorylation of Thr365.
This function of JNK1 seems to be one of possible
mechanisms underlying the anti-Warburg effect and apop-
totic role of JNK1 in cancer (Fig. 4) [146].
Moreover, it was shown that activation of the JNK
pathway by the histone methyltransferase inhibitor chaeto-
cin, which induces apoptosis in cancer cells by inducing
ROS production, resulted in a reduction of glucose uptake
and lactate production in glioma cells [147]. Although the
mechanisms have not been explored in depth, JNK activa-
tion in glioma cells following chaetocin treatment led to a
marked increase in PK activity and decrease of HK2 activity
and expression [147], implying a role for the JNK pathway
in restraining the glycolytic metabolism in glioma cells.
Importantly, culturing cancer cells with elevated con-
centrations of pyruvate increased the activity of JNK1, but
not JNK2, by enhancing ROS production [148]. Mechan-
istically, it was shown that activation of the ROS→JNK1
axis activates the ribosomal kinase p70S6K, which in turn
suppresses glycogen synthase kinase-3β resulting therefore
in augmented activity of glycogen synthase, an enzyme
involved in converting glucose to glycogen, and subsequent
diverting glucose away from the mitochondria [148].
Likewise, glutamine deprivation in osteosarcoma cells sti-
mulates endoplasmic reticulum stress, which leads to the
activation of JNK driving transcription and secretion of IL-
8, needed for osteolysis associated with metastatic breast
cancer [149]. Altogether these observations suggest the
JNK pathway is involved in the regulation of cellular
metabolism in cancer cells. In addition to cancer cells,
JNK1 has been shown to suppress glycolysis in normal
tissue. Knockdown of JNK1 in normal liver cells upregu-
lated the hepatic expression of clusters of genes involved in
glycolysis and in triglyceride synthesis pathways, suggest-
ing that basal activity of JNK1 negatively regulates hepatic
glycolysis and biomass formation [150]. This was further
confirmed by studies using high-fat-fed mice with com-
pound deficiency of JNK1 and JNK2 in hepatocytes, which
exhibited increased expression of glycolytic enzymes and
lactate production accompanied by a reduced rate of mito-
chondrial oxygen consumption. Such effects of JNK1 and
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JNK2 deletion were associated with an upregulation of
genes involved in the PPAR, leading to marked increases in
the rate of fatty acid oxidation, ketogenesis, and improved
hepatic insulin action in these mice. This indicates that
JNK1 and JNK2 in hepatocytes function to reduce glyco-
lysis, fatty acid oxidation, and ketogenesis in response to a
high-fat diet [151].
However, in the literature there are also examples where
activation of the JNK signaling drives aerobic glycolysis,
instead of inhibiting it. Deng et al. [152] reported that
JNK1-mediated phosphorylation of Bad (a BH3-only pro-
apoptotic Bcl-2 family protein) is required for glycolysis
through activation of PFK1. Genetic disruption of Jnk1
alleles or silencing of Jnk1 by small interfering RNA
abrogates glycolysis induced by growth/survival factors,
such as serum or IL-3 [152]. Furthermore, activation of
JNK in cortical neurons has been shown to suppress pyr-
uvate metabolism in mitochondria and promote pyruvate
conversion to lactate in the cytosol by phosphorylating and
inhibiting the PDH complex that normally converts pyr-
uvate to acetyl-CoA, which can then enter into TCA cycle
(Fig. 3) [6]. Thus, by inhibiting PDH, the activity of JNK in
cortical neurons compromises the oxidative metabolism and
favors glycolysis (via lactate production with concomitant
NAD+ regeneration) [153]. Of note, like PKM2, PDH is a
specific substrate of JNK1 [153]. Activation of the JNK
pathway has also been shown to mediate the pro-glycolytic
effect of oncogenic RAS expression in primary human
keratinocytes. Indeed, keratinocyte-overexpressing RAS
mutant exhibited a marked increase in the rate of glycolysis
compared to control cells. Such effect was abolished in
these cells by treatment with several JNK inhibitors, such as
SP600125, indicating that JNK activity plays a central role
in RAS-induced glycolysis [154].
In conclusion, the information outlined here indicate that
JNK signaling (more likely JNK1) acts as negative regulator
of aerobic glycolysis in different types of glycolytic tumors,
suggesting an intricate link between JNK and cellular
metabolism. These studies also provide evidences for JNK
regulating an inextricable crosstalk between apoptosis and
cancer metabolism and opens up an interesting opportunity
to explore the importance of understanding both the func-
tional roles of each JNK protein in the context of tumor
metabolism, in order to validate the therapeutic potential of
JNK inhibition in cancer. As pointed out earlier, restraining
of the JNK signaling is a common trait of glycolytic tumors
[146, 147]. Likewise, survival of many tumors relies on the
constitutive activation of the transcription factor NF-κB,
which restrains JNK-mediated apoptosis (reviewed in ref.
[155]). It would be interesting to understand whether cancers
highly dependent on NF-κB activity are more glycolytic than
tumors with less active NF-κB. Or whether any of the NF-
κB-regulated genes (suppressing JNK signaling) are key
regulators of aerobic glycolysis in cancer cells. Notably, NF-
κB-mediated restraining of JNK-induced apoptosis is also a
mechanistic phenotype activated in response to pro-
inflammatory cytokines (i.e., TNF-α) (reviewed in ref.
[155]). In this regard, it is imperative querying whether
enhanced JNK activation observed in response to TNF-α in
NF-κB-deficient cells is associated with inhibition of aerobic
glycolysis. Of particular attention are also many examples in
the literature in regard to JNK driving aerobic glycolysis.
Therefore, future studies aimed at a better understanding of
JNK signaling in the regulation of inflammation, cell
metabolism, and cancer will likely translate the biology of
JNK signaling into a program of drug discovery for
inflammatory, metabolic, and cancer diseases.
Conclusions and future perspectives
A common characteristic of cancer cells that distinguish
them from their normal counterparts is an increase in gly-
colysis with concomitant lactate production (the Warburg
effect) [6, 7, 11, 12]. This observation has led to intensive
studies of both the molecular mechanisms underlying the
Warburg effect and its cellular function with the goal of
identifying targeted therapies that are selectively cytotoxic
to cancer cells while preserving normal tissue. However,
efforts to translate this knowledge into effective therapy is
still underway and to date very few drugs targeting the
Warburg effect have been approved for clinical evaluation
[63, 64]. The main limitations can be surmised as: (1) the
metabolic phenotype of cancer cells is also shared by
untransformed rapidly proliferating cells, especially cells of
the immune system; (2) most glycolytic enzymes are ubi-
quitously expressed in all mammalian cells and direct tar-
geting of those enzymes could have detrimental side effects.
Therefore, targeting oncogenic signaling pathways that
affect cellular metabolism may overcome in part limitations
of direct targeting of metabolic enzymes. Currently, there
are several therapeutic strategies being used to target
upstream regulators of metabolic pathways, such as PI3K,
AKT, and HIF-1α signaling module [21, 64]. Yet, these
targets are also generally shared by normal cells, compro-
mising the development of safe and efficient inhibitors for
cancer therapy. Therefore, the identification of pathways
that are solely activated in different tumor types is still the
best approach to identify drugs against targets that are
efficacious and specific for tumors with minimal toxicity on
normal cells. In this regard, the BRAF/MEK/ERK pathway
represents an ideal candidate for targeting both oncogene
and metabolism of certain types of tumors, especially
melanomas [98, 106–109], or may work successfully as a
combinatorial regimen with other anticancer drugs [109,
129, 130]. Conversely, activating JNK1 that suppresses
aerobic glycolysis and favors apoptosis may provide
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additional therapeutic avenues for glycolytic cancers exhi-
biting low basal JNK activity, including inflammation-
driven cancers (i.e., HCC) and multiple myeloma [135,
155]. In this respect, it is important to note that inhibition of
either PARP14 or NF-κB activity may achieve inhibition of
tumor metabolism via activation of JNK activity [135, 155].
Further studies into this aspect of cancer cell biology will
help to identify targets that will inhibit certain signaling
pathways while preserving others and therefore will con-
ceive more efficient antineoplastic agents.
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